US$ 22.76
glp-1 drugs eli lilly launches pill, kicking off showdown with Novo Nordisk Lilly is now pharma's top
Description
First, the follow-up data were available for different time frames

Paragraph IV Certifications List

10.1016/j.jad.2012.01.013 [DOI] [PubMed] [Google Scholar] Zheng P., Zeng B., Zhou C., Liu M., Fang Z., Xu X., et al

Interestingly, there was a greater increase in the mean dyskinesia rating scale score in the exenatide-treated group, which necessitated a reduction in l-dopa doses in five patients

Szpunar for her help in creating Table 2 and A
